Quest Diagnostics Stock News

The Enterovirus Diagnostic market research report delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. The Enterovirus Diagnostic report also incorporates the current and future global market outlook in the emerging and developed markets.

Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.

Quest Diagnostics (NYSE:DGX) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations. Valuation & Earnings This table compares Quest Diagnostics and Viridian Therapeutics top-line revenue, earnings per share []

Victory Capital Management Inc. trimmed its position in Quest Diagnostics Incorporated (NYSE:DGX) by 10.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 2,839,262 shares of the medical research companys stock after selling 325,979 shares during the period. Quest Diagnostics comprises approximately 0.4% of Victory Capital Management Inc.s holdings, making the stock its 26th []

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

Viridian Therapeutics (NASDAQ:VRDN) and Quest Diagnostics (NYSE:DGX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership. Analyst Recommendations This is a breakdown of current recommendations for Viridian Therapeutics and Quest Diagnostics, as [] The post Analyzing Viridian Therapeutics (NASDAQ:VRDN) and Quest Diagnostics (NYSE:DGX) appeared first on ETF Daily News .

Galvin Gaustad & Stein LLC boosted its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 28.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,050 shares of the medical research companys stock after purchasing an additional []

Analysts expect that Quest Diagnostics Incorporated (NYSE:DGX) will announce earnings per share of $3.03 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Quest Diagnostics earnings, with the highest EPS estimate coming in at $3.45 and the lowest estimate coming in at $2.80. Quest Diagnostics posted earnings per []

Banque Cantonale Vaudoise lowered its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 2.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,968 shares of the medical research companys stock after selling 462 shares during the []

Huntington National Bank cut its holdings in Quest Diagnostics Incorporated (NYSE:DGX) by 1.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,651 shares of the medical research companys stock after selling 105 shares during the quarter. Huntington National Banks holdings in Quest []

Quest Diagnostics (NYSE:DGX) had its target price lowered by Morgan Stanley from $165.00 to $159.00 in a research report report published on Friday morning, Price Targets.com reports. Morgan Stanley currently has an equal weight rating on the medical research companys stock. DGX has been the subject of several other reports. Deutsche Bank Aktiengesellschaft lifted their []

Quest Diagnostics (NYSE:DGX) had its price target lifted by Wells Fargo & Company from $150.00 to $160.00 in a research note issued to investors on Tuesday, The Fly reports. The firm currently has an equal weight rating on the medical research companys stock. DGX has been the topic of several other reports. Morgan Stanley increased []

Progressives and government watchdog groups on Wednesday condemned House Speaker Nancy Pelosi''s defense of individual stock trading by members of Congress, days after an extensive report revealed dozens of conflicts of interest by lawmakers who own stocks related to the healthcare industry and other sectors Congress is supposed to regulate. After being asked by Business Insider at her weekly press conference whether members of Congress and their spouses should be barred from trading stocks, Pelosi said the practice should be permitted to continue because "we are a free market economy." REPORTER: "Should members of congress and their spouses be banned from trading individual stocks while serving in congress?"\n\nPELOSI: "NoWe are a free market economy. They should be able to participate in that."pic.twitter.com/2SNqSCwFEU Townhall.com (@Townhall.com) 1639585364 Speaking to Business Insider after the press conference, Pelosi''s spokesperson said the STOCK Act which was passed in 2012 and requires members to disclose security transactions and ensure they don''t make individual stock trades based on knowledge they gain as lawmakersprevents members of Congress from insider trading.

Quest Diagnostics serves one in three adult Americans and half the physicians and hospitals in the United States each year. The post New Jersey-based Quest Diagnostics acquires Andersons Labtech Diagnostics appeared first on UPSTATE BUSINESS JOURNAL .

Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).